Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC.

Christopoulos P, Kirchner M, Endris V, Stenzinger A, Thomas M.

J Thorac Dis. 2018 Jun;10(Suppl 17):S1989-S1991. doi: 10.21037/jtd.2018.05.61. No abstract available.

2.

Molecular dissection of large cell carcinomas of the lung with null immunophenotype.

Harms A, Endris V, Winter H, Kriegsmann M, Stenzinger A, Schirmacher P, Warth A, Kazdal D.

Pathology. 2018 Jun 26. pii: S0031-3025(17)30718-3. doi: 10.1016/j.pathol.2018.03.005. [Epub ahead of print]

PMID:
29958730
3.

Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.

Bochtler T, Endris V, Reiling A, Leichsenring J, Schweiger MR, Klein S, Stögbauer F, Goeppert B, Schirmacher P, Krämer A, Stenzinger A.

J Natl Compr Canc Netw. 2018 Jun;16(6):677-682. doi: 10.6004/jnccn.2018.7012.

PMID:
29891518
4.

NRG1 Fusions in KRAS Wild-type Pancreatic Cancer.

Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger MS, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H.

Cancer Discov. 2018 May 25. pii: CD-18-0036. doi: 10.1158/2159-8290.CD-18-0036. [Epub ahead of print]

PMID:
29802158
5.

Genomic features of renal cell carcinoma with venous tumor thrombus.

Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S.

Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z.

6.

Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data.

Budczies J, Pfarr N, Romanovsky E, Endris V, Stenzinger A, Denkert C.

BMC Bioinformatics. 2018 Apr 24;19(1):157. doi: 10.1186/s12859-018-2159-5.

7.

Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma.

Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, Fröhling S, Wickenhauser C, Jordan K, Hurtz HJ, Müller LP, Rüssel J, Weber T.

Eur J Haematol. 2018 Jul;101(1):115-118. doi: 10.1111/ejh.13072. Epub 2018 May 11.

PMID:
29624748
8.

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.

Lehners N, Ellert E, Xu J, Hillengass J, Leichsenring J, Stenzinger A, Goldschmidt H, Andrulis M, Raab MS.

Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443450. [Epub ahead of print]

PMID:
29616856
9.

Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.

Kriegsmann M, Harms A, Kazdal D, Fischer S, Stenzinger A, Leichsenring J, Penzel R, Longuespée R, Kriegsmann K, Muley T, Safi S, Warth A.

Pathol Res Pract. 2018 Mar;214(3):408-416. doi: 10.1016/j.prp.2017.12.018. Epub 2018 Jan 2.

PMID:
29487011
10.

Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.

Ahadova A, Gallon R, Gebert J, Ballhausen A, Endris V, Kirchner M, Stenzinger A, Burn J, von Knebel Doeberitz M, Bläker H, Kloor M.

Int J Cancer. 2018 Jul 1;143(1):139-150. doi: 10.1002/ijc.31300. Epub 2018 Feb 23.

PMID:
29424427
11.

EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.

Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M.

Int J Cancer. 2018 Jun 15;142(12):2589-2598. doi: 10.1002/ijc.31275. Epub 2018 Jan 24.

PMID:
29363116
12.

Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix.

Jesinghaus M, Konukiewitz B, Foersch S, Stenzinger A, Steiger K, Muckenhuber A, Groß C, Mollenhauer M, Roth W, Detlefsen S, Weichert W, Klöppel G, Pfarr N, Schlitter AM.

Mod Pathol. 2018 May;31(5):829-839. doi: 10.1038/modpathol.2017.184. Epub 2018 Jan 12.

PMID:
29327707
13.

Integrative genomic and transcriptomic analysis of leiomyosarcoma.

Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S.

Nat Commun. 2018 Jan 10;9(1):144. doi: 10.1038/s41467-017-02602-0.

14.

Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas.

Bosic M, Kirchner M, Brasanac D, Leichsenring J, Lier A, Volckmar AL, Oliveira C, Buchhalter I, Stögbauer F, Zivkovic-Perisic S, Goeppert B, Schirmacher P, Penzel R, Endris V, Stenzinger A.

Pathology. 2018 Apr;50(3):327-332. doi: 10.1016/j.pathol.2017.10.011. Epub 2017 Dec 18.

PMID:
29269125
15.

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.

Budczies J, Denkert C, Győrffy B, Schirmacher P, Stenzinger A.

BMC Med Genomics. 2017 Dec 6;10(1):74. doi: 10.1186/s12920-017-0308-8.

16.

A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.

Volckmar AL, Sültmann H, Riediger A, Fioretos T, Schirmacher P, Endris V, Stenzinger A, Dietz S.

Genes Chromosomes Cancer. 2018 Mar;57(3):123-139. doi: 10.1002/gcc.22517. Epub 2017 Dec 20. Review.

PMID:
29205637
17.

Corrigendum to 'Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux' [The International Journal of Antimicrobial Agents 50/1 (2017) 55-62].

Matt U, Selchow P, Molin MD, Strommer S, Sharif O, Schilcher K, Andreoni F, Stenzinger A, Zinkernagel AS, Zeitlinger M, Sander P, Nemeth J.

Int J Antimicrob Agents. 2018 Jan;51(1):122. doi: 10.1016/j.ijantimicag.2017.10.012. Epub 2017 Nov 14. No abstract available.

PMID:
29150181
18.

Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.

Muckenhuber A, Berger AK, Schlitter AM, Steiger K, Konukiewitz B, Trumpp A, Eils R, Werner J, Friess H, Esposito I, Klöppel G, Ceyhan GO, Jesinghaus M, Denkert C, Bahra M, Stenzinger A, Sprick MR, Jäger D, Springfeld C, Weichert W.

Clin Cancer Res. 2018 Jan 15;24(2):351-359. doi: 10.1158/1078-0432.CCR-17-2180. Epub 2017 Nov 3.

PMID:
29101303
19.

Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.

Faehling M, Schwenk B, Kramberg S, Eckert R, Volckmar AL, Stenzinger A, Sträter J.

Oncotarget. 2017 Sep 13;8(44):77897-77914. doi: 10.18632/oncotarget.20857. eCollection 2017 Sep 29.

20.

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.

Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S.

Oncotarget. 2017 May 23;8(43):74049-74057. doi: 10.18632/oncotarget.18200. eCollection 2017 Sep 26.

21.

Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.

Leichsenring J, Volckmar AL, Kirchner M, Kazdal D, Kriegsmann M, Stögbauer F, Bockmayr T, Klauschen F, Herth FJF, Penzel R, Warth A, Schirmacher P, Endris V, Stenzinger A.

Genes Chromosomes Cancer. 2018 Feb;57(2):70-79. doi: 10.1002/gcc.22509. Epub 2017 Nov 16.

PMID:
29044880
22.

Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study.

Freitag MT, Kesch C, Cardinale J, Flechsig P, Floca R, Eiber M, Bonekamp D, Radtke JP, Kratochwil C, Kopka K, Hohenfellner M, Stenzinger A, Schlemmer HP, Haberkorn U, Giesel F.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):340-347. doi: 10.1007/s00259-017-3854-6. Epub 2017 Oct 16.

PMID:
29038888
23.

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T.

Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. No abstract available.

PMID:
29030332
24.

EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.

Fassunke J, Ihle MA, Lenze D, Lehmann A, Hummel M, Vollbrecht C, Penzel R, Volckmar AL, Stenzinger A, Endris V, Jung A, Lehmann U, Zeugner S, Baretton G, Kreipe H, Schirmacher P, Kirchner T, Dietel M, Büttner R, Merkelbach-Bruse S.

Virchows Arch. 2017 Oct;471(4):509-520. doi: 10.1007/s00428-017-2226-8. Epub 2017 Sep 8.

PMID:
28884371
25.

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.

Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jäger D, Dahm M, Huber B, Schöning T, Sedlaczek O, Stenzinger A, Halama N, Daniel V, Leuchs B, Angelova A, Rommelaere J, Engeland CE, Springfeld C, Ungerechts G.

BMC Cancer. 2017 Aug 29;17(1):576. doi: 10.1186/s12885-017-3604-y.

26.

Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model.

Brecht L, Wallwiener M, Schott S, Domschke C, Dinkic C, Golatta M, Schuetz F, Fluhr H, Stenzinger A, Kirchner M, Sohn C, Rom J.

Surg Endosc. 2018 Feb;32(2):1002-1011. doi: 10.1007/s00464-017-5778-4. Epub 2017 Aug 24.

PMID:
28840380
27.

Qualitative Comparison Between Carrier-based and Classical Tissue Microarrays.

Lisenko K, Leichsenring J, Zgorzelski C, Longuespée R, Casadonte R, Harms A, Kazdal D, Stenzinger A, Warth A, Kriegsmann M.

Appl Immunohistochem Mol Morphol. 2017 Oct;25(9):e74-e79. doi: 10.1097/PAI.0000000000000529.

PMID:
28777146
28.

Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.

Dietz S, Harms A, Endris V, Eichhorn F, Kriegsmann M, Longuespée R, Stenzinger A, Sültmann H, Warth A, Kazdal D.

Int J Cancer. 2017 Nov 1;141(9):1841-1848. doi: 10.1002/ijc.30881. Epub 2017 Jul 24.

PMID:
28699162
29.

Mutations in BRCA2 and taxane resistance in prostate cancer.

Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x.

30.

Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.

Pfarr N, Darb-Esfahani S, Leichsenring J, Taube E, Boxberg M, Braicu I, Jesinghaus M, Penzel R, Endris V, Noske A, Weichert W, Schirmacher P, Denkert C, Stenzinger A.

Genes Chromosomes Cancer. 2017 Oct;56(10):758-766. doi: 10.1002/gcc.22480. Epub 2017 Jul 25.

PMID:
28639280
31.

Precision oncology based on omics data: The NCT Heidelberg experience.

Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S.

Int J Cancer. 2017 Sep 1;141(5):877-886. doi: 10.1002/ijc.30828. Epub 2017 Jun 21.

PMID:
28597939
32.

Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer.

Kazdal D, Harms A, Endris V, Penzel R, Kriegsmann M, Eichhorn F, Muley T, Stenzinger A, Pfarr N, Weichert W, Warth A.

Br J Cancer. 2017 Jul 11;117(2):220-226. doi: 10.1038/bjc.2017.155. Epub 2017 May 30.

33.

Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux.

Matt U, Selchow P, Dal Molin M, Strommer S, Sharif O, Schilcher K, Andreoni F, Stenzinger A, Zinkernagel AS, Zeitlinger M, Sander P, Nemeth J.

Int J Antimicrob Agents. 2017 Jul;50(1):55-62. doi: 10.1016/j.ijantimicag.2017.02.022. Epub 2017 May 12. Erratum in: Int J Antimicrob Agents. 2017 Nov 14;:.

PMID:
28506804
34.

Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.

Budczies J, Bockmayr M, Klauschen F, Endris V, Fröhling S, Schirmacher P, Denkert C, Stenzinger A.

Genes Chromosomes Cancer. 2017 Aug;56(8):651-659. doi: 10.1002/gcc.22468. Epub 2017 May 31.

PMID:
28466543
35.

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.

Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, Lasitschka F, Penzel R, Dietel M, Brors B, Gröschel S, Glimm H, Schirmacher P, Renner M, Fröhling S, Stenzinger A.

Oncoimmunology. 2017 Jan 27;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017.

36.

MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma.

Hess AK, Müer A, Mairinger FD, Weichert W, Stenzinger A, Hummel M, Budach V, Tinhofer I.

Eur J Cancer. 2017 May;77:3-12. doi: 10.1016/j.ejca.2017.02.018. Epub 2017 Mar 26.

PMID:
28347920
37.

Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.

Affolter A, Samosny G, Heimes AS, Schneider J, Weichert W, Stenzinger A, Sommer K, Jensen A, Mayer A, Brenner W, Mann WJ, Brieger J.

Head Neck. 2017 Apr;39(4):623-632. doi: 10.1002/hed.24557. Epub 2017 Feb 21.

PMID:
28221700
38.

Genetic Profiling of Cancers of the Digestive System: Biological Insights and Clinical Implications.

Stenzinger A, Weichert W.

Pathobiology. 2017;84(6):306-322. doi: 10.1159/000446545. Epub 2017 Feb 9.

39.

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.

Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, Hinderhofer K, Heilig CE, Kramer M, Thiede C, Endris V, Kirchner M, Stenzinger A, Benner A, Bornhäuser M, Ehninger G, Ho AD, Jauch A, Krämer A; Study Alliance Leukemia Investigators.

Blood. 2017 Mar 9;129(10):1333-1342. doi: 10.1182/blood-2016-09-738161. Epub 2017 Jan 24.

40.

Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.

Jesinghaus M, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M, Penzel R, Endris V, Arsenic R, Hermann G, Stenzinger A, Weichert W, Pfarr N, Klöppel G.

Mod Pathol. 2017 Apr;30(4):610-619. doi: 10.1038/modpathol.2016.220. Epub 2017 Jan 6.

41.

Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.

Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Geörg C, Richter D, Pfarr N, Pfütze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S.

Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001180.

42.

Mutations of cancer-related genes in benign tumors: the example of hidradenoma papilliferum.

Pfarr N, Stenzinger A.

Hum Pathol. 2017 Apr;62:246-247. doi: 10.1016/j.humpath.2016.09.034. Epub 2016 Nov 16. No abstract available.

PMID:
27865794
43.

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.

Volckmar AL, Endris V, Bozorgmehr F, Lier C, Porcel C, Kirchner M, Leichsenring J, Penzel R, Thomas M, Schirmacher P, Warth A, Stenzinger A.

Diagn Pathol. 2016 Nov 18;11(1):133.

44.

Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.

Pfarr N, Penzel R, Endris V, Lier C, Flechtenmacher C, Volckmar AL, Kirchner M, Budczies J, Leichsenring J, Herpel E, Noske A, Weichert W, Schneeweiss A, Schirmacher P, Sinn HP, Stenzinger A.

Genes Chromosomes Cancer. 2017 Apr;56(4):255-265. doi: 10.1002/gcc.22431. Epub 2016 Nov 23.

PMID:
27792260
45.

Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.

Leichsenring J, Volckmar AL, Magios N, Morais de Oliveira CM, Penzel R, Brandt R, Kirchner M, Bozorgmehr F, Thomas M, Schirmacher P, Warth A, Endris V, Stenzinger A.

Genes Chromosomes Cancer. 2017 Mar;56(3):214-220. doi: 10.1002/gcc.22427. Epub 2016 Nov 30.

PMID:
27750395
46.

Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.

Goeppert B, Ernst C, Baer C, Roessler S, Renner M, Mehrabi A, Hafezi M, Pathil A, Warth A, Stenzinger A, Weichert W, Bähr M, Will R, Schirmacher P, Plass C, Weichenhan D.

Epigenetics. 2016 Nov;11(11):780-790. Epub 2016 Sep 3.

47.

PARP inhibition in BRCA2-mutated prostate cancer.

Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. No abstract available.

PMID:
27687312
48.

Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.

Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S.

Ann Oncol. 2017 Jan 1;28(1):142-148. doi: 10.1093/annonc/mdw446.

PMID:
27687311
49.

Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.

Tinhofer I, Stenzinger A, Eder T, Konschak R, Niehr F, Endris V, Distel L, Hautmann MG, Mandic R, Stromberger C, Weichert W, Budach V.

Ann Oncol. 2016 Dec;27(12):2262-2268. doi: 10.1093/annonc/mdw426. Epub 2016 Sep 28.

PMID:
27681865
50.

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Denkert C, Stenzinger A, Salat C, Sinn B, Schem C, Endris V, Klare P, Schmitt W, Blohmer JU, Weichert W, Möbs M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Loi S, Untch M, von Minckwitz G, Nekljudova V, Loibl S.

Oncotarget. 2016 Oct 18;7(42):67686-67698. doi: 10.18632/oncotarget.11891.

Supplemental Content

Loading ...
Support Center